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606Objective: Joint guidelines on myocardial revascularization were published by the European Society of Cardi-
ology and European Association for Cardiothoracic Surgery: Patients with left main stem, proximal left anterior
descending, or 3-vessel disease should be discussed with a surgeon before revascularization, and ad hoc percu-
taneous coronary intervention has no elective indication in these categories. We assess the impact of the guide-
lines on referral patterns to a cardiac surgery service at a large-volume cardiac center in the United Kingdom.
Methods: Joint guidelines were published in August 2010. All patients with severe disease undergoing percu-
taneous coronary intervention at one institution were identified 6 months before (January to June 2010) and
6 months after (January to June 2011) their introduction. Decision-making and surgical referral were determined
from minutes of multidisciplinary meeting.
Results:A total of 197 patients underwent elective percutaneous coronary intervention pre-guidelines, ofwhom62
had severe disease. Only 6 patients (9%) were discussed at a multidisciplinary meeting before intervention. After
introduction of the guidelines, elective percutaneous coronary interventions were performed in 164 patients, of
whom 42 had surgical disease. Only 8 patients (17%) were discussed at a multidisciplinary meeting before inter-
vention (P¼ not significant). Follow-up was a median of 480 (380-514) days for the pre-guideline group and 104
(31-183) days for the post-guideline group.Ad hoc percutaneous coronary intervention in surgical disease occurred
in 8 patients (14%) pre-guidelines and was unchanged for 9 patients (26%) post-guidelines (P¼ not significant).
Conclusions: Despite recommendation by both cardiology and cardiac surgical bodies and widespread public-
ity, a significant number of patients in this single-center study are not receiving optimal treatment recommended
by these guidelines. (J Thorac Cardiovasc Surg 2014;147:606-10)Earn CME credits at
http://cme.ctsnetjournals.org
Coronary revascularization improves both symptoms and sur-
vival in patients with significant coronary artery disease.1-3
This can be achieved by coronary artery bypass grafting
(CABG) or percutaneous coronary intervention (PCI). The
safety and efficacy of both procedures have been well
established, but there is great variability in their use in
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The Journal of Thoracic and Cardiovascular Surgbetween surgeons and cardiologists was required to guide
practice on the basis of current best evidence. A group
composed of cardiac surgeons and interventional and nonin-
terventional cardiologists has recently produced joint guide-
lines for the European Society of Cardiology (ESC) and
EuropeanAssociation for Cardiothoracic Surgery (EACTS).5
These guidelines provide a framework to assist in decision-
making for patients requiring elective coronary
revascularization.
TheESC/EACTSGuidelines state that in patients with sta-
ble coronary artery disease, those with 1- or 2-vessel disease,
not involving the proximal left anterior descending (LAD) ar-
tery, should be offered PCI.More extensive disease involving
the left main stem (LMS) or proximal LAD, or those with
3-vessel disease should be considered for CABG in the first
instance. Specific mention is made of high-risk groups, in-
cluding patients with chronic kidney disease, left ventricular
failure, and diabetes, inwhom surgery is the preferred option.
All patients with coronary artery disease who are being
considered for revascularization will undergo a diagnostic
angiogram. Intervention performed during this procedureery c February 2014
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
EACTS ¼ European Association for Cardiothoracic
Surgery
ESC ¼ European Society of Cardiology
LAD ¼ left anterior descending
LMS ¼ left main stem
PCI ¼ percutaneous coronary intervention
RCA ¼ right coronary artery
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receiving ad hoc PCI, up to 30% were potentially candi-
dates for CABG.6 The guidelines make a specific recom-
mendation that stable patients should have intervention
deferred. This allows discussion with a surgeon and pro-
vides time for the patient to understand the options available
to them.5
The ESC/EACTSGuidelines place particular emphasis on
a multidisciplinary approach and suggest that a Heart Team
containing both cardiologists and surgeons discuss complex
patients before intervention. Furthermore, patients being
treated against the guidelines, for whatever reason, should
be discussed with the Heart Team before intervention.5 The
aim of this study is to evaluate the effect of the publication
of the ESC/EACTS Guidelines on revascularization practice
at a cardiothoracic unit in the United Kingdom.
PATIENTS AND METHODS
Patient Population
The study was carried out at St George’s Hospital, London, United
Kingdom, a teaching hospital with a tertiary Cardiology and Cardiotho-
racic Surgery Unit representing a significant proportion of the coronary
revascularization workload of NHS London.
Timing of Study
The ESC/EACTS Guidelines on Coronary Revascularization were pub-
lished in August 2010 and presented in detail to the multidisciplinary team
at our hospital. To study the impact of the guidelines, patients undergoing
coronary revascularization from January to June 2011 were studied.
Patients who had undergone revascularization from January to June 2010
were used as control population. This allowed time for the guidelines to
be incorporated into practice and prevent seasonal bias.
Database
All patients undergoing revascularization at St George’s Hospital during
the study period were identified. Surgical patients were identified from the
Central Cardiac Audit Database, and those undergoing PCI were identified
from The British Cardiovascular Intervention Society database. These data
are collected during every PCI procedure, with a final set of data entered
after patient discharge. All patients having undergone PCI during the study
periods were identified. Those undergoing previous cardiac surgery were
excluded.
A database of all patients discussed at the multidisciplinary meeting at
St George’s Hospital during the stated time periods was compiled from
contemporaneous minutes recorded at each meeting. Minutes are written
by a dedicated member of staff at each meeting recording the diagnosis,The Journal of Thoracic and Camanagement plan, and reasons for deviation from expected practice. The
minutes are then circulated to all physicians and surgeons who attend the
meeting for approval before finalization.
Definitions
Elective procedures were those carried out on stable patients usually as
a day case procedure. Urgent procedures were those carried out as an inpa-
tient, usually for non–ST-segment elevationmyocardial infarction or unsta-
ble angina. Emergency procedures were those carried out before the start of
the next working day, usually primary PCI due to ST-segment elevation
myocardial infarction.
Coronary artery stenosis was defined as narrowing of 50% or greater of
vessel diameter at angiography. Three-vessel disease was defined as steno-
sis of the right coronary artery (RCA), LAD, and circumflex artery.
Outcomes
The notes or electronic patient records were reviewed for all patients
and correlated with the multidisciplinary meeting database to determine
which patients had been discussed by the multidisciplinary team. Second-
ary outcomes investigated were vessels intervened on, subsequent revascu-
larization, and in-hospital mortality.
Data are presented as a mean standard deviation. Categoric data were
tabulated for chi-square and Fisher exact test. To compare mean differ-
ences, the normality test (Shapiro–Wilk) (age) was performed for continu-
ous data and Student t tests were performed for independent samples.RESULTS
Revascularization Activity
From January to June 2010, before publication of the
guidelines, there were a total of 504 PCIs performed, ex-
cluding those patients who had undergone previous cardiac
surgery. Of these, 197 were elective, 147 were urgent, and
160 were emergency. There were 264 isolated CABGs
performed during the same time period. From January to
June 2011, after publication of the guidelines, 498 PCIs
were performed, 164 elective, 138 urgent, and 196 emer-
gency. There were 260 isolated CABGs performed during
the same period. There was no significant change in activity
of elective PCI (P ¼ .34) or CABG (P ¼ .4) after publica-
tion of the guidelines.Referral Patterns to Cardiac Surgery
In 2010, 67 patients (34%) undergoing elective PCI had
disease potentially suitable for CABG. Only 6 (9%) of
these were discussed with a cardiac surgeon before inter-
vention. This compares with 48 (29%) of all elective
PCIs in 2011, of which 8 (17%) were discussed with a sur-
geon (Figure 1). A small number (2010 n ¼ 5, 2011 n ¼ 6)
of these PCIs were for in-stent restenosis and excluded from
further analysis. The demographics of both groups were
similar. There was no difference in the proportion of proce-
dures carried out since the introduction of the guidelines
(34% vs 29%; P ¼ .26).
During both time periods, the demographics of the
groups not discussed with a surgeon were similar. The aver-
age age was 65  6 years in 2010 and 67  8 years in 2011
(P ¼ .03). A significant number of patients had diabetes inrdiovascular Surgery c Volume 147, Number 2 607
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FIGURE 1. Patients with severe coronary artery disease who underwent elective PCI. LAD, Left anterior descending.
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hypertension (40 vs 19; P ¼ .13) and smoking (30 vs 14;
P ¼ .38) (Table 1).
Of those who were not discussed with a surgeon in 2010,
40 patients (71%) had proximal LAD disease, 14 patients
(25%) had 3-vessel disease, and 2 patients (4%) had
LMS stenosis. In 2011, 22 patients (65%) had disease in
proximal LAD, 8 patients (24%) had 3-vessel disease,
and 4 patients (11%) has LMS disease. Table 2 shows the
completeness of revascularization for each of these cate-
gories of disease.
Of the 2010 cohort with 3-vessel disease, 10 patients
(71%) had a single-vessel PCI and the remaining patients
had 2 vessels treated. Of these, 4 patients (29%) underwent
further PCI after a mean of 18 weeks (range, 0-30 weeks).
There was 1 death (7%), and mean follow-up was 480
days (range, 380-514 days). In 2011, 6 (67%) of those
with 3-vessel disease had single-vessel intervention, and
the other had 2 vessels treated. During follow-up, 2 patients
(22%) underwent further PCI after 10 weeks (range, 6-14TABLE 1. Demographics of patients undergoing elective percutaneous
coronary intervention for severe coronary artery disease who were not
discussed with a surgeon before intervention
Demographic 2010 (n ¼ 56) 2011 (n ¼ 34) P value
Male/female 40/16 31/3 .03
Age (y) 65  11 67  11 .26
Previous MI 15 10 .59
Previous PCI 16 9 .83
Diabetes 15 5 .18
Hypertension 40 19 .13
Cerebrovascular accident 1 0 1
Renal failure 0 0 N/A
Smoking history 30 14 .38
Good LV function 56 30 .32
MI, Myocardial infarction; PCI, percutaneous coronary intervention; LV, left
ventricle; N/A, not available.
608 The Journal of Thoracic and Cardiovascular Surgweeks). There were no deaths. Mean follow-up was 104
days (range, 31-183 days).Ad Hoc Percutaneous Coronary Intervention
Activity
A significant proportion of elective PCIs with disease po-
tentially suitable for CABGwere intervened on in an ad hoc
fashion. There were 8 (14%) in 2010 and 9 (26%) in 2011.
In 2010, 5 patients (63%) had proximal LAD disease, and
the remainder had 3-vessel disease. In 2011, 6 patients
(67%) had proximal LAD disease, and the remainder had
3-vessel disease.
In the 2010 group, of those with proximal LAD involved,
all 5 had PCI to LAD. Two patients had disease in a second
vessel that was not revascularized. Those with 3-vessel dis-
ease had PCI to proximal LAD only, proximal LAD þ
RCA, and circumflex þ RCAwith staged PCI to proximal
LAD (Table 3).TABLE 2. Completeness of revascularization in patients with severe
coronary artery disease not discussed with a surgeon
Disease pattern 2010 (n ¼ 56) 2011 (n ¼ 34)
Isolated proximal LAD disease
Complete revascularization 21 13
Incomplete revascularization 0 0
Proximal LAD disease þ other stenosis
Complete revascularization 8 4
Complete revascularization – staged 1 0
Incomplete revascularization 10 5
LMS disease
Complete revascularization 0 0
Incomplete revascularization 2 4
3-vessel disease
Complete revascularization 0 1
Complete revascularization – staged 4 2
Incomplete revascularization 10 5
LAD, Left anterior descending; LMS, left main stem.
ery c February 2014
TABLE 3. Completeness of revascularization of patients who
underwent ad hoc percutaneous coronary intervention for stable
coronary artery disease
Disease pattern 2010 (n ¼ 8) 2011 (n ¼ 9)
Proximal LAD
Complete revascularization 3 4
Incomplete revascularization 0 0
Proximal LAD disease þ other stenosis
Complete revascularization 0 1
Complete revascularization – staged 0 0
Incomplete revascularization 2 1
3-vessel disease
Complete revascularization 0 0
Complete revascularization – staged 1 0
Incomplete revascularization 2 3
LAD, Left anterior descending.
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ment, 4 had the LAD stented, 1 had the LADþ obtuse mar-
ginal, and 1 had the RCAwith staged PCI to LAD. Of those
with 3-vessel disease, 1 had the LAD stented, 1 had the
circumflex stented, and 1 had both stented (Table 3). The
demographics of both groups were statistically similar.
There was no difference in the incidence of ad hoc PCI be-
tween the 2 groups (14% vs 26%; P ¼ not significant).
DISCUSSION
This study has clearly demonstrated that despite the re-
cent publication of guidelines supported by both the ESC
and EACTS, many elective patients requiring coronary
revascularization are not receiving management based on
these recommendations.
Before the publication of the ESC/EACTS Guidelines in
2010, there had been no recent joint guidance on elective
myocardial revascularization produced by medical and
surgical societies. The ESC Guidelines were published in
2005,7 the same year as the American College of Cardiol-
ogy/American Heart Association Guidelines were pro-
duced.8 It is notable that of the combined 70 authors of
these guidelines, only 1 was a surgeon.9 Furthermore, the
most recent guidance on CABG was published by the
American Heart Association in 2004.10 This has led to
a disparity in consensus between surgeons and cardiolo-
gists, resulting in a variation in the management of patients
requiring elective revascularization. A review of the 16,142
patients in the NewYork State Registry with coronary artery
disease showed that of those with indications for surgery ac-
cording to American College of Cardiology/American
Heart Association Guidelines, only 53% were recommen-
ded for surgery.4 The results of our study looking at the
ESC/EACTS Guidelines are similar.
The SYNTAX trial was a prospective randomized con-
trolled trial of PCI versus CABG in 1800 patients with
LMS and triple-vessel coronary artery disease. The trial
stratified patients by the angiographic complexity of theirThe Journal of Thoracic and Cadisease using the SYNTAX score. At 1 year, the groups
had similar overall death rates, but cardiac death was higher
in the PCI group compared with CABG (3.7% vs 2.1%,
P ¼ .05). Furthermore, revascularization rates were signif-
icantly higher in the PCI group (13.5% vs 5.9%, P<.001).
However, CABG had a higher stroke rate than PCI (2.2% vs
0.6%, P ¼ .003). At St George’s Hospital during the same
period, stroke rates were 1.86% versus 0.3% for CABG and
PCI, respectively. These 1-year outcomes of SYNTAX,
although not included in the ESC/EACTS Guidelines,
became available when they were published, giving further
support to the use of surgery in 3-vessel and LMS disease.11
The accompanying editorial states the importance of the
heart team, which is reinforced by the guidelines.12
The benefit of CABG in comparison with PCI is becom-
ing increasingly evident.13 The 3-year outcomes of the
SYNTAX trial, published after our study, found that
patients with 3-vessel disease undergoing CABG have sig-
nificant reduction in all-cause mortality (9.5% vs 5.7%,
P ¼ .02) and repeat revascularization (10% vs 19.4%,
P< .001). Of note, stroke rates become similar in both
groups (3.2% vs 2%, P ¼ .07).
However, the trial has shown similar outcomes for those
with LMS disease and low/intermediate SYNTAX score
and thosewith a low SYNTAX score and 3-vessel disease.14
Of note, the ESC/EACTS Guidelines do not differentiate
patients by SYNTAX score.
Analysis of high-risk groups included in the SYNTAX
trial has shown significantly higher mortality in diabetic pa-
tients undergoing PCI compared with nondiabetic persons
(13.6% vs 6.9%; P ¼ .002). Mortality after CABG was
similar in these 2 groups (8.7% vs 6.1%; P ¼ .153). Major
adverse cardiovascular and cerebrovascular events were
higher in diabetic patients undergoing PCI compared with
CABG (37% vs 22.9%; P¼ .001), driven mainly by repeat
revascularization rate (20% vs 12.9%; P<.001).15
More recently, the outcomes of the FREEDOM trial,
a trial of 1900 patients with diabetes and multivessel coro-
nary artery disease randomized to receive PCI or CABG,
has been published. The primary end point of death, myo-
cardial infarction, and stroke occurred more often in the
PCI group (26.6% vs 18.7%, P ¼ .005). At 5 years, those
undergoing PCI had significantly higher mortality than
the CABG group (16.3% vs 10.9%, P¼ .049).16 This again
supports surgery in high-risk groups with severe coronary
artery disease.
Ad hoc PCI is common practice in the United States, but
there are little data on its prevalence in Europe. In a study us-
ing the New York Registry, it has been shown that approxi-
mately 30% of patients undergoing ad hoc PCI were
potentially suitable for surgical revascularization. However,
the study does not report on outcomes in this specific group.6
Potential benefits include shorter hospital stay, reduced
procedural complications, and lower contrast dose. Therdiovascular Surgery c Volume 147, Number 2 609
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discussion and therefore inability to fully inform patients re-
garding their options.17 The fact that ad hoc PCI continues
against the ESC/EACTS Guidelines is of concern.
As the range of options for revascularization in patients
with coronary artery disease expands, it is becoming in-
creasingly important for surgeons and cardiologists to
work together to provide the best possible service for
each individual patient. This involves having up-to-date
knowledge of best evidence, discussing patients at a multi-
disciplinary team meeting, and providing patients with in-
formation required to decide on their preferred treatment.
Clinical governance already dictates that all of these discus-
sions should be clearly documented, and scrutiny of this
will undoubtedly increase in the future.
There are a variety of reasons why current practice does
not seem to have been influenced by the introduction of the
ESC/EACTS Guidelines. The changes required would
significantly alter the incidence of PCI and CABG. Further-
more, many cardiologists do not believe the Joint European
Guidelines reflect current best evidence, especially with the
publication of the SYNTAX trial subsequent to these guide-
lines. This study has shown that current practice does not
fully use the Heart Team, a practice that would need to
change to fully incorporate the guidelines.
Study Limitations
Although this is a single-center study, it was carried out at
a large academic cardiothoracic center representing a signif-
icant proportion of the revascularization practice across
London.
CONCLUSIONS
The recent publication of the joint consensus on elective
revascularization has provided a framework to assist
decision-making in patients with coronary artery disease.
Currently, there is a significant number of patients not
receiving the optimal treatment recommended. Further
work is required to increase multidisciplinary team working
and awareness of current guidelines.610 The Journal of Thoracic and Cardiovascular SurgReferences
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